Objective: To determine whether kidney function level and its rate of decline in the immediate predialysis period among veterans transitioning to end-stage renal disease (ESRD) predict postdialysis mortality and hospitalization. Patients and Methods: In 19,985 veterans transitioning to ESRD during the period October 1, 2007, to March 30, 2014, we examined kidney function and its slope over the final year of the pre-ESRD(prelude) period. Two categories of low vs high estimated glomerular filtration rate (eGFR, dichotomized at 10 mL/ min/1.73 m 2 ) and slow vs fast slope (dichotomized at À10 mL/min/1.73 m 2 /y) were combined into 4 groups. Their associations with 12-month post-ESRD all-cause and cardiovascular (CV) mortality and hospitalization rates were examined in adjusted models accounting for clinical characteristics and laboratory measurements at transition. Results: Patients, 66AE11 years old, and 34% blacks, had a median (interquartile range) eGFR at transition and slope of 9.7 (7.1-13.3) mL/min/1.73 m 2 and À10.5 (À18.8 to À5.9) mL/min/1.73 m 2
M ore than 120,000 persons transition to end-stage renal disease (ESRD) each year in the United States, mostly with dialysis.
1,2 Mortality rates for dialysis patients are especially high in the first months after transition and a study investigating nursing home patients suggested that functionality in this early posttransition period was also substantially reduced. 2, 3 Thus, discussions have emerged pertaining to the benefit of early initiation of dialysis therapy in older persons, especially those with slower progressing kidney disease. Ironically, estimated glomerular filtration rate (eGFR) at the time of transition has progressively become higher, indicating a trend toward earlier transition, or a more aggressive dialysis initiation. As of 2014, the US average eGFR at initiation was 10.2 mL/min/1.73 m 2 . 1 Despite these trends, the optimal timing of ESRD transition still remains controversial. Although some studies and clinical guidelines have previously suggested that early initiation may be beneficial, [4] [5] [6] [7] [8] [9] a clinical trial and other observational studies have suggested otherwise. [10] [11] [12] [13] [14] [15] However, many of the latter studies were limited in data on the rate of disease progression and laboratory measures from the period before transition, which are important drivers of eGFR levels at transition. 16 As eGFR and its slopes have become more readily available in clinical practice, 17 it may be of importance to examine the use of both metrics in risk prediction.
In addition to the controversy of ESRD timing in the US population, it is uncertain whether this relationship is externally valid for the US veteran population. The veteran population is composed of predominately older males with likely different ailments compared with that of the greater US population. Preliminary data from the United States Renal Data System (USRDS) "Transition-of-Care-in-CKD" Special Study Center have shown that 11% of incident US ESRD patients each year are veterans, and that high mortality rates in the first months after transition also exist in this veteran population.
1,2 Moreover, it was suggested that veterans initiating ESRD with a Veterans Affairs (VA) health care provider may have better survival, and a lower probability of initiating at a higher eGFR, compared with those initiating with a non-VA provider. 1, 2, 18 Finally, a study investigating solely eGFR slope in the veteran population reported that a rapid decline was associated with higher long-term post-ERSD mortality. 19 However, no study has examined whether veterans who transition to ESRD with both a lower eGFR and a less progressive disease have better or worse early post-ESRD outcomes. We sought to examine these outcomes in a contemporary cohort of US veteran patients transitioning to ESRD and hypothesized that the combination of a slower disease progression and lower kidney function level on transition is associated with better immediate post-ESRD outcomes.
PATIENTS AND METHODS

Study Population and Data Source
We retrospectively analyzed data from the Transition-of-Care-in-CKD study, which investigated veterans transitioning to ESRD between October 1, 2007, and March 30, 2014. 1 The source population comprised 85,505 veterans identified from the USRDS. We excluded 1958 patients for missing follow-up information, 32,280 patients with missing data on VA measured serum creatinine, and 29,724 with no available creatinine measurement within 31 days before transition. To calculate eGFR slope using a mixed-effects regression model during the 12 months before ESRD, we further required that these patients have at least 2 eGFR measurements (including the measure within 31 days before transition) and over 30 days apart. After excluding patients without these criteria, and slope outliers at 0.5 and 99.5 percentiles, our final cohort comprised 19,985 veterans with both 31-day measured pre-ESRD (prelude) eGFR and 12-month prelude eGFR slope (Supplemental Figure 1 , available online at http://www.mayoclinicproceedings.org).
This study was approved by the institutional review boards of the Memphis and Long Beach Veterans Affairs Medical Centers. Because of the large sample size, patient anonymity, and nonintrusive nature of the research, the written consent requirement was exempt.
Demographic, Clinical, and Laboratory Measurements Data from 3 national databasesdUSRDS, VA, and Centers for Medicare & Medicaid Services (CMS)dwere combined to determine baseline characteristics. Marital status was obtained from VA records. Receipt of pre-ESRD care was obtained from USRDS CMS 2728 Medical Evidence Form. Preexisting comorbidity information was extracted from VA and CMS data sets using International Classification of Diseases, Ninth Revision Diagnostic and Current Procedural Terminology codes. Charlson comorbidity index was calculated without renal disease. Presence of a comorbidity was assigned using a 1 inpatient or 2 outpatient visits algorithm.
Prelude laboratory measurements were sourced from VA databases only. Data on serum creatinine and other laboratory measurements were obtained from the VA Corporate Data Warehouse LabChem and Decision Support System National Data Extracts Laboratory Results files, respectively. Data on body mass index (BMI; calculated as the weight in kilograms divided by the height in meters squared) and blood pressure were obtained from the VA Corporate Data Warehouse Vital Signs file. The closest measurement to transition within the 31-day prelude period was used in analyses as baseline value.
Exposure Measurement
The primary exposure was the combination of 31-day prelude eGFR and rate of kidney function change in the 12-month prelude period. The eGFR was calculated using the Chronic Kidney Disease Epidemiology Collaboration equation. 20 Based on the approximate median of the cohort and previous studies, 11, 12, 19 eGFR was dichotomized as less than 10 and greater than or equal to 10 mL/min/1.73 m 2 to represent low and high eGFR at transition, respectively. Disease progression (slope) was calculated using mixedeffects linear regression to ascertain the annual eGFR slope before transition. Based on the approximate median of the cohort and previous study, 19 slopes were dichotomized as more than À10 and less than or equal to À10 mL/min/1.73 m 2 /y to represent slow and fast eGFR slope, respectively. A total of 4 combined groups (2 Â 2) were created as our primary exposure, with a low 31-day eGFR and a slow 12-month eGFR slope group as the reference.
Outcome Assessment
The outcomes of interest were 12-month allcause mortality, 12-month cardiovascular (CV) mortality, and 12-month hospitalization rate after transition. Cardiovascular reasons for death were obtained from the USRDS. Data on all-cause events, including death and hospitalizations, were sourced from VA, CMS, and USRDS data sets. Patients were followed from the start of ESRD until death, kidney transplantation, lost to follow-up, end of the 12-month follow-up period, or September 2, 2014, whichever occurred first. For CV mortality, the last date of follow-up was June 30, 2014.
Statistical Analyses
Baseline patient characteristics were described as proportion, mean AE SD, or median (interquartile range [IQR]), and differences across eGFR groups were compared with tests of c 2 , analysis of variance, or Kruskal-Wallis, where appropriate.
Predictors of a low eGFR and slow slope (reference¼all other kidney profiles), higher eGFR (reference¼low eGFR), and faster disease progression (reference¼slow slope) were examined using logistic regression.
The relationship of the combination of eGFR and slope with 12-month all-cause or CV mortality was examined using Cox proportional hazard models. To evaluate the association of the combined eGFR and slope groups with 12-month hospitalization incidence rate, Poisson and negative binomial regression models were used.
For each outcome, 3 models of adjustment were used: (1) unadjusted model; (2) casemixeadjusted model, which included the time interval between the last eGFR measurement and transition date, age, sex, race, ethnicity, incidence year, marital status, Charlson comorbidity index, diabetes, ischemic heart disease (ISHD), myocardial infarction, congestive heart failure (CHF), cerebrovascular disease, and chronic obstructive pulmonary disease (COPD); and (3) case-mix þ malnutritioninflammation cachexia syndromeeadjusted model, which included case-mix model variables and baseline measurements of bicarbonate, blood urea nitrogen, hemoglobin, albumin, phosphorus, calcium, potassium, BMI, and systolic and diastolic blood pressure.
Sensitivity Analyses
We conducted sensitivity analyses to examine the robustness of the observed associations. The eGFR and slope-mortality association was evaluated across strata of clinical characteristics. Wald tests for interaction were performed in the fully adjusted models. Because fluctuations in eGFR may occur, a subgroup of 5285 patients was excluded if hospitalized within the 12-month prelude period with a primary diagnosis of an acute kidney injury (AKI) (International Classification of Diseases, Ninth Revision code 584 or 586), or were indicated as recovered renal function by the USRDS within 60 days from transition.
Next, we examined additional categorizations of combined eGFR and slope. We examined granular groups guided by approximate quartiles of the cohort. A total of 16 groups were created, representing eGFR (<7, 7-<10, 10-<13, and !13 mL/min/1.73 m 2 ) and slope (>À5, À5 to >À10, À10 to >À15, and À15 mL/min/1.73 m 2 /y). In addition, we calculated percentile ranks (value, 1-100) for eGFR and slope, respectively. A low percentile would represent a lower eGFR or slower slope, and a high percentile would represent a higher eGFR or faster slope. These percentiles were summed together (eGFR percentile plus slope percentile) or subtracted from each other (eGFR percentile minus slope percentile) and their respective association with all-cause mortality was evaluated using restricted cubic splines.
Finally, we calculated propensity scores to account for patient differences. For propensity score models, we examined associations of (1) eGFR and included eGFR slope as a covariate and (2) eGFR slope with eGFR as a covariate. We used the propensity score in multiple analyses, including the propensity score in covariate adjustment, stratification based on propensity score tertiles, and finally, matching by propensity score. 21 Data for demographic characteristics were missing for less than 0.15% and were imputed using a missing category. Laboratory variables were missing on average 11% and were imputed by means. Analyses were conducted using SAS Enterprise Guide (7.1) and Stata/MP Version 14.
RESULTS
Baseline clinical characteristics stratified by eGFR and slope groups are presented in Table 1 . The cohort was 66AE11 years old, and included 2% females and 34% blacks. The median (IQR) of eGFR at transition and slope was 9.7 (7.1-13.3) mL/min/1.73 m 2 and À10.5 (À18.8 to À5.9) mL/min/1.73 m 2 /y, respectively. In our cohort, 26% of patients transitioned to ESRD with a low eGFR and slow slope and were more likely to be black, have pre-ESRD nephrology and dietician care, and had a lower prevalence of diabetes, depression, and COPD.
Predictors of a Low eGFR and Slow eGFR Slope
In adjusted analyses, compared with all other disease profiles, black race and higher albumin were associated with higher odds of initiating with a low eGFR and slow slope ( 
Predictors of a High eGFR or Fast eGFR Slope
Among all patients who met eGFR criteria (n¼21,543), the presence of CHF consistently had the highest odds of transitioning with a high eGFR across all models (Supplemental Table 1A , available online at http://www. mayoclinicproceedings.org). Conversely, in the fully adjusted model, predictors of lower eGFR included female sex, black race, Hispanic ethnicity, cerebrovascular disease, and higher albumin, blood urea nitrogen, and phosphorus.
In our analytical cohort, predictors of a faster slope included higher eGFR, hospitalization at transition, Charlson comorbidity index, and COPD across all models (Supplemental Table 1B In unadjusted analyses, a low eGFR and slow slope was associated with the lowest risk of 12-month all-cause and CV mortality ( Figure 1A and B). After additional levels of adjustments, this relationship still persisted, as a low eGFR and slow slope was associated with the lowest risk of 12-month all-cause and CV mortality, although slightly attenuated with CV mortality. The greatest eGFR and fastest slope was associated with the highest risk of 12-month all-cause and CV mortality (hazard ratio [ Table 2A and B, available online at http://www.mayoclinicproceedings.org).
Likewise, we observed that a low eGFR and slow slope was associated with lower Figure 3 , available online at http://www. mayoclinicproceedings.org). However, many of the observed relationships across strata were largely attenuated because of a small number of events and sample size.
We also used the eGFR and slope composite sum or difference score to evaluate the combined effect. In summed rank variables, there was a linear association with 12-month all-cause mortality after full adjustment, where patients with a low eGFR and slow slope had the lowest risk for mortality (reference¼100; Figure 2A ). When examining the difference in percentile ranks, we observed a U-shaped association with 12-month all-cause mortality.
Patients with either a low eGFR and fast slope, or high eGFR and slow slope, had the highest adjusted risks of all-cause mortality compared with the reference of 0 (patients with combination of either low eGFR and slow slope, or high eGFR and fast slope) ( Figure 2B ).
Propensity Score Sensitivity Analyses
To account for characteristic differences, we calculated propensity scores of transitioning to ESRD with a high or low eGFR (Supplemental Table 3A , available online at http://www. mayoclinicproceedings.org). After matching, higher eGFR was associated with approximately 30% higher risk of 12-month all-cause mortality among 12,532 matched patients across all levels of adjustment (Table 3) . Among the analytical cohort, additional propensity score analyses resulted in similar findings under all models. Likewise, we calculated propensity scores of transitioning to ESRD with a slow or fast eGFR slope (Supplemental Table 3B with a lower hospitalization incidence rate (Figure 3 ). Similar to mortality analyses, patients with an aggressive disease profile had the highest 12-month hospitalization rate (incidence rate ratio [95% CI], 1.39 [1.34-1.44]) after full adjustment. The observed associations were similar in sensitivity analyses, including when modeled with negative binomial regression, excluding patients for an AKI or recovered function, and under more granular groups of eGFR at transition and slope (Supplemental Table 2C ).
DISCUSSION
In a contemporary cohort of 19,985 veterans who transitioned to ESRD, the combination of a lower kidney function with slower kidney disease progression, or low eGFR and slow slope, was associated with better early ESRD outcomes including lower all-cause and CV mortality risk and hospitalizations. The kidney disease profile of higher eGFR combined with fastest disease progression was associated with the highest risk of 12-month morbidity and mortality outcomes. These relationships remained robust in sensitivity analyses including propensity scores, which may mitigate the likelihood of selection bias on transition to ESRD.
Previous studies investigating US population cohorts have primarily relied on eGFR at transition, [10] [11] [12] [13] [14] and have been limited in examining confounding due to nutritional status, 16 especially from before transition, including slopes. Similar to past studies, we also observed higher mortality risk among patients with higher eGFR at transition, but after additionally accounting for eGFR slope, nutritional parameters, and propensity for earlier transition. Many studies have demonstrated higher mortality risk with eGFR slope in many populations, including the community, elderly, and patients with early stage chronic kidney disease. [22] [23] [24] [25] [26] However, few studies have examined pre-ESRD eGFR trajectories and post-ESRD mortality. 19, 27 O'Hare et al 27 reported that a catastrophic loss of eGFR was associated with the highest risk of 1-year all-cause mortality, yet not in longer periods of follow-up (2-5 years). We observed similar findings, in that an aggressive kidney disease profile including a fast slope was associated with higher early mortality risk. In addition, Sumida et al 19 examined the eGFR slope-mortality association, with effect modification by last eGFR before transition. The authors found that among patients with a last eGFR of greater than or equal to 10 mL/ min/1.73 m 2 , a rapid loss was not associated with higher mortality risk (reference¼ slow decline [<À5 mL/min/1.73 m 2 /y]). We, however, did observe lower early mortality risk for patients initiating with a low eGFR and slow slope. In addition to differences in reference groups, we evaluated early mortality, whereas Sumida et al examined long-term follow-up (median, 2 years), 19 and it is possible that the eGFR slope-mortality association among patients with a high eGFR at transition may be impacted by time-varying dialysis treatment covariates 1, 28 and thus mitigating the long-term mortality risk.
It has been suggested that early initiators may lose renal function faster compared with later initiators as a repercussion of dialysis treatment, especially in the early months posttransition with thrice-weekly hemodialysis as compared with incremental hemodialysis. 11, 29 Dialysis may more strongly affect early initiators, thereby leading to a more rapid loss of residual renal function, as well as increased inflammation, cachexia, and body mass loss, all of which have been noted as predictors of mortality risk among incident ESRD patients. 11, [30] [31] [32] Furthermore, decline in kidney function may be an indicator for other underlying conditions including atherosclerosis, oxidative stress, malnutrition, and other cardiovascular diseases, which can contribute to higher morbidity and mortality. 19 The lowest mortality risk, observed in patients with a low eGFR and slow slope, may actually be indicative of better pre-ESRD care. Indeed, 80% and 31% of these patients had pre-ESRD nephrology and dietician care, respectively, compared with markedly less in other groups. Similar to observed trends in a previous study, 27 the patients with a low eGFR and slow slope at initiation were less likely to initiate in a hospital and had fewer pre-ESRD hospitalizations. Thus, these patients may have had a better management of health care, including closer monitoring of disease progression and a planned, or maybe delayed, transition at a lower eGFR level. These high levels of care may be carried through post-ESRD, such that these patients may be less likely to be hospitalized and have a lower mortality risk after transition to ESRD. Thus together, both eGFR and disease progression in combination are important risk factors in post-ESRD morbidity and mortality, and eGFR alone may no longer be a sole factor when transitioning to ESRD. 17, 23 These data may have clinical and public health implications because they suggest that a low eGFR and slow slope in the immediate prelude period is associated with more favorable early ESRD outcomes. It is suggestive that delaying transition until a lower eGFR may afford better outcomes, including a lesser life burden from time on dialysis.
This study should be qualified for several potential limitations. Because of the observational nature of the study design, residual confounding cannot be completely excluded, 34 compared with examining a change in percent or eGFR category. 17 To our knowledge, this is one of the largest studies to investigate both ESRD timing and disease progression with early ESRD mortality and morbidity in US veterans. High eGFR & fast slope 12-month hospitalization incidence rate ratio FIGURE 3. Association of combined 31-day prelude eGFR and 12-month eGFR slope with 12-month hospitalization incidence rate ratio. eGFR ¼ estimated glomerular filtration rate; prelude ¼ pre-ESRD.
CONCLUSION
We observed that in veteran patients transitioning to ESRD, transitioning with a low eGFR and slow slope was associated with a lower risk of 12-month mortality and hospitalization, and this relationship was independent of laboratory markers. This relationship remained consistent across numerous sensitivity analyses. Together, these results further support the notion that an early transition to dialysis may not be as beneficial as once thought and additional studies are warranted to clarify this relationship. SUPPLEMENTAL ONLINE MATERIAL Supplemental material can be found online at http://www.mayoclinicproceedings.org. Supplemental material attached to journal articles has not been edited, and the authors take responsibility for the accuracy of all data.
ACKNOWLEDGMENTS
Abbreviations and Acronyms: AKI = acute kidney injury; BMI = body mass index; CHF = congestive heart failure; CMS = Centers for Medicare & Medicaid Services; COPD = chronic obstructive pulmonary disease; CV = cardiovascular; eGFR = estimated glomerular filtration rate; ESRD = endstage renal disease; HR = hazard ratio; IQR = interquartile range; ISHD = ischemic heart disease; OR = odds ratio; prelude = pre-ESRD; USRDS = United States Renal Data System; VA = Veterans Affairs
